Jon Napitupulu

EG 427, a biotech company developing targeted genetic medicines for neurological conditions, secured €27 million in Series B funding....

Phoenix Molecular Designs (PhoenixMD) has initiated Phase 2 clinical trials (Dauntless-1) for PMD-026, a first-in-class pan-RSK inhibitor, in combination...

Saudi Arabia is rapidly becoming a hub for clinical trials in the Middle East, with over 400 active studies...

Neurona Therapeutics, a clinical-stage biotherapeutics company, is initiating its Phase 3 EPIC clinical trial for NRTX-1001, a regenerative cell...

Shattuck Labs announced positive preclinical data from a toxicology study of SL-325, a high-affinity DR3 blocking antibody being developed...

SELLAS Life Sciences announced positive Phase 2a trial data for SLS009 (tambiciclib), a CDK9 inhibitor, combined with Brukinsa (zanubrutinib)...

PolarityBio’s SkinTE received Breakthrough Therapy Designation from the FDA for treating Wagner Grade 1 Diabetic Foot Ulcers (DFUs). This...

Nuwellis, Inc. announced updated findings from the AVOID-HF study, published in the Journal of the American College of Cardiology:...

Vaxxas, a clinical-stage biotech company, has completed enrollment for its Phase I clinical trial of an avian influenza A...

Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...